Prescribing ADHD Stimulants by Telehealth in 2026 and After

Most ADHD stimulants are Schedule II controlled substances under 21 CFR 1308.12: amphetamine, methamphetamine, methylphenidate and lisdexamfetamine all sit there. That one fact explains why ADHD has been the most scrutinized corner of virtual care since 2020. Every rule that applies to telehealth prescribing of controlled substances applies to stimulants at full strength, and several state laws and the DEA's own proposal treat Schedule II more strictly than anything else.

What is allowed through December 31, 2026?

Under the DEA and HHS fourth temporary extension (90 FR 61301, December 31, 2025, codified at 21 CFR 1307.41), a DEA-registered practitioner may prescribe Schedule II through V drugs by telemedicine without a prior in-person medical evaluation until the end of the day on December 31, 2026. The conditions are the ones that applied to the earlier extensions:

• The prescription is for a legitimate medical purpose in the usual course of professional practice.
• It follows a communication by an interactive telecommunications system as defined at 42 CFR 410.78(a)(3), which means real-time audio and video, with audio-only allowed only where that definition allows it.
• The practitioner holds a DEA registration that covers Schedule II, or is exempt from registration.
• Everything else in 21 CFR part 1306 is met, including the rule that Schedule II prescriptions cannot be refilled (21 CFR 1306.12(a)).

The temporary rule says nothing about state law. A stimulant prescription that satisfies DEA can still be unlawful in the patient's state.

What happens to stimulant patients on January 1, 2027?

Nobody knows yet, which is the honest answer and the one to plan around. One of three things will be in effect: a final special registration rule, a fifth temporary extension, or nothing, in which case the Ryan Haight Act's in-person evaluation requirement at 21 U.S.C. 829(e) applies again. Our post on what changes on January 1, 2027 walks through each one. Unlike buprenorphine for opioid use disorder, ADHD medication has no standing regulatory pathway that survives a lapse.

The fallback that does survive is the in-person evaluation itself. Once the prescribing practitioner has seen the patient in person, DEA's position, restated in the fourth extension's preamble, is that the Ryan Haight Act's remote prescribing restrictions no longer apply to that practitioner-patient relationship, however long ago the visit was. For a stimulant practice, the most valuable field in the EHR right now is "has the prescriber examined this patient in person, and when?"

What did DEA propose for Schedule II under the special registration?

The proposed rule (Special Registrations for Telemedicine and Limited State Telemedicine Registrations, 90 FR 6541, January 17, 2025) would split prescribers into two tiers. A basic Telemedicine Prescribing Registration would cover Schedules III through V only. Schedule II would need an Advanced Telemedicine Prescribing Registration, limited to listed specialties: psychiatrists, hospice and palliative care physicians, physicians treating patients in long-term care facilities, pediatricians, neurologists, and mid-level practitioners board certified in psychiatric, psychological, hospice, palliative, pediatric or neurological care unrelated to pain treatment.

Two further limits were proposed for Schedule II, and DEA said it might adopt one, both or neither:

• The prescriber would have to be physically located in the same state as the patient when issuing the prescription (proposed 21 CFR 1306.45(b)).
• Special registration prescriptions for Schedule II drugs would have to stay under 50 percent of the prescriber's total Schedule II prescriptions in a calendar month (proposed 21 CFR 1306.45(c)).

A final rule went to the White House Office of Information and Regulatory Affairs on August 25, 2026, and the Unified Agenda targets November 2026. Nothing is final and the text may change. Two things are clear from the proposal, though: a family nurse practitioner without a qualifying board certification would not get Schedule II authority under it, and an all-virtual practice prescribing stimulants across many states would collide with either location limit. The full proposal is in our special registration explainer.

Which states already limit Schedule II by telehealth?

State law applies regardless of DEA, and Schedule II is where states are most specific. Examples from statutes we have checked:

• Florida. Fla. Stat. § 456.47(2)(c) bars Schedule II prescribing by telehealth except for a psychiatric disorder, hospital inpatient treatment, hospice patients and nursing home residents. ADHD practices rely on the psychiatric disorder exception; the statute does not define the term. Details in our Florida Schedule II post.
• Connecticut. Conn. Gen. Stat. § 19a-906(c) bars Schedules I through III by telehealth, with an exception for Schedule II or III drugs used to treat psychiatric disabilities or substance use disorders, which must be prescribed electronically and consistently with the Ryan Haight Act.
• Ohio. Ohio Admin. Code 4731-11-09 requires an initial in-person physical exam before a first Schedule II prescription to a new patient, with exceptions that include treatment of mental health conditions and the federal telemedicine exceptions.
• Arizona. A.R.S. § 36-3602(E) lets Schedule II be prescribed only after an in-person or audio-visual examination, so an audio-only intake does not support a stimulant prescription.
• Alabama. Ala. Code § 34-24-704 requires, for any controlled substance prescribed by telehealth, a synchronous visit and at least one in-person encounter with the prescriber in the prior 12 months.
• Louisiana. State Board of Medical Examiners rules (La. Admin. Code tit. 46, pt. XLV, § 7513) require an in-person visit within the past year before prescribing a controlled substance by telemedicine, unless the patient is at a licensed, DEA-registered facility.

Other states do not touch stimulants at all. Oklahoma's telemedicine limit at 59 Okla. Stat. § 478.1 is aimed at opiates, benzodiazepines and carisoprodol. Each state page in our telehealth law index lists the controlled substance rule we found and its citation.

What else does a stimulant prescription need in each state?

• A DEA registration in the patient's state. The registration follows the patient. Our sisters file them: White Glove APRN for NPs, White Glove PA for PAs and White Glove IMLC for physicians.
• A state controlled substance registration where one exists. Connecticut, Delaware, Maryland, Louisiana, Alabama and the District of Columbia are among the jurisdictions that require one on top of DEA. The NP-focused state CSR and CDS list on White Glove APRN is a good map.
• PDMP access and a mandatory check. Many states require a PDMP query before a Schedule II prescription; the timing and frequency rules differ. See PDMP checks for telehealth prescribers.
• Electronic prescribing for controlled substances. The SUPPORT Act of 2018 requires electronic prescribing for controlled substances covered by Medicare Part D, and many states require it for controlled substance prescriptions regardless of payer.

What did the Done Global case add?

A model to avoid, described in detail. On July 7, 2026, Done Global's founder and CEO, Ruthia He, was sentenced to 72 months in prison and a $1 million fine, and its clinical president to 24 months, after a San Francisco jury convicted them in November 2025. According to the Justice Department announcement, republished by HHS-OIG, the government's case was that the company used its "technology platform, compensation structure, and clinical protocols" to distribute more than 37 million Adderall pills and defrauded insurers of more than $12 million. The lesson operators draw from it is not that telehealth ADHD care is unlawful. It is that clinician pay tied to prescriptions, auto-renewing subscriptions, short visit templates and pressure on clinicians to prescribe become evidence. Our longer read is what the Done Global prosecution means for operators.

What should a virtual ADHD practice do before December?

1. Build the in-person list. For every active stimulant patient: has the current prescriber seen them in person, when, and where is it documented.
2. Price in-person evaluations. Clinic partners, a mobile model, or transfers to local prescribers. Decide the cost per patient before December, not after.
3. Check prescribers against the proposed specialty list. Which clinicians are psychiatrists, pediatricians, neurologists or board-certified psychiatric NPs, and which are not. Do not restructure on the proposal alone, but know the answer.
4. Audit state rules for every patient state. Florida, Connecticut, Ohio, Arizona and Alabama all add something.
5. Review compensation and visit templates with counsel. Pay that rises with prescriptions written is the first thing a prosecutor reads.

Our DEA Telemedicine Readiness engagement ($1,450) builds the in-person inventory and the decision tree for each January 1 outcome; the 50-State Telehealth Matrix ($2,950 for one service line) maps the state prescribing rules for counsel. Rule history lives on the DEA telemedicine rules hub. None of this is legal advice.